Irinotecan lung cancer

Han, J. Y., Lim, H. S., Shin, E. S., et al. (2006) Comprehensive analysis of UGTIA polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-ceU lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24, 2237-2244. 

Radiation sensitization with irinotecan in two human lung cancer xenografts has been reported (42). In these experiments, CPT-11 was administered in nontoxic doses 1 h prior to a single dose of irradiation. In other reports radiation sensitization with CPT occurred during or after irradiation (43). 

Takeda K, Negoro S, Kudoh S, et al. Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. BrJ Cancer 1999 79(9-10) 1462-1467. 

Kobayashi K, Shinbara A, Kamimura M, et al. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer. Cancer Chemother Pharmacol 1998 42(1 ) 53—58. 

Fukuoka M, Masuda N, Kudoh S, Negoro S. Irinotecan in small-cell lung cancer—Japanese trials. Oncology (Huntingt) 2000 14(7 Suppl 5) 57-62. 

Font A, Sanchez JM, Taron M et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase lAl (UGTIAI) polymorphism. Invest New Drugs 2003 21 435 43. 

Irinotecan Inhibits topoisomerase I Colorectal cancer, gastroesophageal cancer, nonsmall cell and small cell lung cancer Diarrhea, nausea, vomiting Diarrhea, myelosuppression, nausea and vomiting... 

It has been used to treat leukemia. Other anticancer drugs have been modified from Camptotheca acuminata. Topotecan is used to treat ovarian and small-lung cancers. Irinotecan is used to treat metastatic colorectal cancer. 

Patients with small cell lung cancer (the most aggressive type) show the best responses to platinum-based combination regimens, including cisplatin and etoposide or cisplatin and irinotecan. The topoisomerase I inhibitor topotecan is used as second-line monotherapy in patients who have failed a platinum-based regimen. 

The results of this effort were a detailed pattern of structure-activity relationships (Figure 16.2), and the production of two compounds, topotecan 3[8] and irinotecan 4[9], which were approved for clinical use in 1996, the main indications being ovarian and small-cell lung cancer for the former and metastatic colorectal cancer for the latter. Irinotecan is a water-soluble prodrug of the active compound SN-38 (5) Figure 16.3). Several reviews of this phase of research have been published [10-12]. 

Sandler A. Irinotecan therapy for small-cell lung cancer. Oncology 2002 16 419 38. 

Topotecan and irinotecan both act by inhibiting topoisomerase I (topo I) enzymes, thereby inhibiting DNA replication. They are cell cycle-specific agents with most activity for cells in the S phase. Topotecan is used for treatment of refractory metastatic ovarian carcinoma and small cell lung cancer. It also may be useful in the treatment of head and neck cancer. Irinotecan is indicated for the treatment of metastatic carcinoma of the colon or rectum. 

Clinical uses Topotecan ovarian cancer, small cell and non-small cell lung cancer Irinotecan metastatic colon and rectal carcinoma Small cell and non-small cell lung cancer, gastric cancer, germ cell cancers, leukemias and lymphomas. 

Han, J.Y., Lim, H.S., Shin, E.S., Yoo, Y.K., Park, Y.H., Lee, J.E., Kim, H.T. and Lee, J.S. (2008) Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 59, 69-75. 

Masuda N, Fukoka M, Negro S, et al. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced nonsmall cell lung cancer (NSCLC), a multicenter phase III study. Proc Am Soc Clin Oncol 1999 18 1774 (Abstract). 

Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002 346 85-91. 

Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced nonsmall-cell lung cancer. Cancer Chemother Pharmacol 2003 51 403-406. 

CP carboplatin-paclitaxel 5-FU 5-fluorouracil HNSCC head and neck squamous cell carcinoma IFL irinotecan, 5-fluorouraciI, leucovorin N number of patients NR not reported CRC colorectal cancer NSCLC nonsmall cell lung cancer OS overall survival PFS progression-free survival RR response rate RT radiotherapy. 

Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K. Potential interactions between irinotecan and rifampin in a patient with sm all-cell lung cancer. IntJ Clin Oncol (2004) 9,206-9. 

Irinotecan + cisplatin Mixture of two liposomes Small-cell lung cancer... 

Shao N, Jin S, Zhu W. An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2012 7(2) 470-2. 

---